Skip to main content
NCBI home page
Anesthesia Progress logoLink to Anesthesia Progress
. 1988 Mar-Apr;35(2):43–47.

Reversal Agents in Sedation and Anesthesia: A Review

Jay A Anderson
PMCID: PMC2148592  PMID: 3137841

Abstract

This paper reviews the use of prototypic drugs for reversal of the effects produced by anesthetic and sedative agents. Efficacy and toxicity information is presented for naloxone (as used to reverse opioids), physostigmine (as used for reversal of sedatives), and Flumazenil (a new specific benzodiazepine receptor antagonist). Naloxone is very useful and specific for reversing adverse and life-threatening respiratory depression caused by narcotic drugs and should be used in these situations. Physostigmime has been advocated in incremental doses for reversing sedative effects in patients who are obtunded or depressed after having received benzodiazepines, droperidol, scopolamine, opioids, and phenothiazines. Flumazenil has been shown to readily antagonize the sedative, respiratory depressant, anxiolytic, muscle relaxant, anticonvulsant, amnestic, and anesthetic effects of the benzodiazepines; it appears to have tremendous potential for use in anesthesia, conscious sedation, and emergency medicine when available.

Full text

PDF
43

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Artru A. A., Hui G. S. Physostigmine reversal of general anesthesia for intraoperative neurological testing: associated EEG changes. Anesth Analg. 1986 Oct;65(10):1059–1062. [PubMed] [Google Scholar]
  2. Ashton C. H. Benzodiazepine overdose: are specific antagonists useful. Br Med J (Clin Res Ed) 1985 Mar 16;290(6471):805–806. doi: 10.1136/bmj.290.6471.805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bidwai A. V., Stanley T. H., Rogers C., Riet E. K. Reversal of diazepam-induced postanesthetic somnolence with physostigmine. Anesthesiology. 1979 Sep;51(3):256–259. doi: 10.1097/00000542-197909000-00016. [DOI] [PubMed] [Google Scholar]
  4. Bourke D. L., Rosenberg M., Allen P. D. Physostigmine: effectiveness as an antagonist of respiratory depression and psychomotor effects caused by morphine or diazepam. Anesthesiology. 1984 Nov;61(5):523–528. [PubMed] [Google Scholar]
  5. Darragh A., Lambe R., Brick I., Downie W. W. Reversal of benzodiazepine-induced sedation by intravenous Ro 15-1788. Lancet. 1981 Nov 7;2(8254):1042–1042. doi: 10.1016/s0140-6736(81)91233-2. [DOI] [PubMed] [Google Scholar]
  6. Darragh A., Lambe R., Kenny M., Brick I. Tolerance of healthy volunteers to intravenous administration of the benzodiazepine antagonist Ro 15-1788. Eur J Clin Pharmacol. 1983;24(4):569–570. doi: 10.1007/BF00609905. [DOI] [PubMed] [Google Scholar]
  7. Estilo A. E., Cottrell J. E. Hemodynamic and catecholamine changes after administration of naloxone. Anesth Analg. 1982 Apr;61(4):349–353. [PubMed] [Google Scholar]
  8. Farsang C., Kapocsi J., Vajda L., Varga K., Malisak Z., Fekete M., Kunos G. Reversal by naloxone of the antihypertensive action of clonidine: involvement of the sympathetic nervous system. Circulation. 1984 Mar;69(3):461–467. doi: 10.1161/01.cir.69.3.461. [DOI] [PubMed] [Google Scholar]
  9. Garber J. G., Ominsky A. J., Orkin F. K., Quinn P. Physostigmine-atropine solution fails to reverse diazepam sedation. Anesth Analg. 1980 Jan;59(1):58–60. [PubMed] [Google Scholar]
  10. Klotz U., Ziegler G., Ludwig L., Reimann I. W. Pharmacodynamic interaction between midazolam and a specific benzodiazepine antagonist in humans. J Clin Pharmacol. 1985 Sep;25(6):400–406. doi: 10.1002/j.1552-4604.1985.tb02866.x. [DOI] [PubMed] [Google Scholar]
  11. Klotz U., Ziegler G., Reimann I. W. Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man. Eur J Clin Pharmacol. 1984;27(1):115–117. [PubMed] [Google Scholar]
  12. Lauven P. M., Schwilden H., Stoeckel H., Greenblatt D. J. The effects of a benzodiazepine antagonist Ro 15-1788 in the presence of stable concentrations of midazolam. Anesthesiology. 1985 Jul;63(1):61–64. doi: 10.1097/00000542-198507000-00009. [DOI] [PubMed] [Google Scholar]
  13. Mannelli M., Maggi M., De Feo M. L., Cuomo S., Forti G., Moroni F., Giusti G. Naloxone administration releases catecholamines. N Engl J Med. 1983 Mar 17;308(11):654–655. doi: 10.1056/NEJM198303173081113. [DOI] [PubMed] [Google Scholar]
  14. Michaelis L. L., Hickey P. R., Clark T. A., Dixon W. M. Ventricular irritability associated with the use of naloxone hydrochloride. Two case reports and laboratory assessment of the effect of the drug on cardiac excitability. Ann Thorac Surg. 1974 Dec;18(6):608–614. doi: 10.1016/s0003-4975(10)64408-6. [DOI] [PubMed] [Google Scholar]
  15. Pandit U. A., Kothary S. P., Samra S. K., Domino E. F., Pandit S. K. Physostigmine fails to reverse clinical, psychomotor, or EEG effects of lorazepam. Anesth Analg. 1983 Jul;62(7):679–685. [PubMed] [Google Scholar]
  16. Patel J. B., Martin C., Malick J. B. Differential antagonism of the anticonflict effects of typical and atypical anxiolytics. Eur J Pharmacol. 1982 Dec 24;86(2):295–298. doi: 10.1016/0014-2999(82)90331-4. [DOI] [PubMed] [Google Scholar]
  17. Spaulding B. C., Choi S. D., Gross J. B., Apfelbaum J. L., Broderson H. The effect of physostigmine on diazepam-induced ventilatory depression: a double-blind study. Anesthesiology. 1984 Nov;61(5):551–554. doi: 10.1097/00000542-198411000-00013. [DOI] [PubMed] [Google Scholar]
  18. Taff R. H. Pulmonary edema following naloxone administration in a patient without heart disease. Anesthesiology. 1983 Dec;59(6):576–577. doi: 10.1097/00000542-198312000-00019. [DOI] [PubMed] [Google Scholar]

Articles from Anesthesia Progress are provided here courtesy of American Dental Society of Anesthesiology

RESOURCES